MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that James E. Doyle
and Maneesh K. Arora were elected to company’s board of directors at its
annual meeting of stockholders. Lionel N. Sterling has served as a
director of Exact since 2010 and was reelected to the board.
Gov. James E. Doyle, 68, served two terms as governor of Wisconsin.
Prior to being elected governor in 2002, Gov. Doyle served three terms
as Wisconsin’s attorney general. Gov. Doyle also served as the district
attorney of Dane County, Wisconsin and worked in private practice. His
extensive public service includes service in the Peace Corps in Tunisia
and as an attorney in a federal legal services office on the Navajo
Indian Reservation. Gov. Doyle earned a bachelor’s degree from the
University of Wisconsin-Madison and a law degree from Harvard Law
School. Gov. Doyle is of counsel at Foley & Lardner LLP, an
international law firm, and a partner of Doyle & Boyce Strategies, a
consultant to several national foundations. He serves on the board of
trustees of the Kaiser Family Foundation, a leading non-profit
organization focused on national health issues.
Maneesh K. Arora, 45, has served as Exact’s chief operating officer
since February 2012 and as a senior vice president since April 2009,
when he joined the company. Mr. Arora also served as the company’s chief
financial officer from April 2009 to August 2013. Prior to joining
Exact, Mr. Arora worked for Third Wave Technologies Inc., a molecular
diagnostics company, from 2003 until its acquisition by Hologic Inc. in
July 2008. During his time at Third Wave, Mr. Arora was responsible for
business strategy and commercial operations before being promoted to
chief financial officer in January 2006. Mr. Arora earned a bachelor’s
degree in economics from the University of Chicago and an MBA from the
Kellogg Graduate School of Management at Northwestern University.
Lionel N. Sterling, 76, has served as a director since July 2010.
Since 1987, he has served as president of Equity Resources Inc., a
private investment firm. He previously co-founded and served as managing
partner of the private investment firm Whitehead/Sterling. He also has
served as chairman of the board of directors of Rayovac Corp., executive
vice president and director of United Brands Co., and sector executive
and chief financial officer of American Can Co. Mr. Sterling also serves
as a director of GlucoTec Inc., a medical software firm focusing on
in-hospital insulin control. He previously served as a director of
i-STAT Corp., a medical diagnostics company; Third Wave
Technologies Inc., a molecular diagnostics company; and Molecular
Insight Pharmaceuticals, Inc., a clinical-stage biopharmaceutical
company. Mr. Sterling earned a bachelor’s degree from Brooklyn College
and an MBA from New York University.
“We are pleased to welcome Jim and Maneesh to Exact’s board, and we are
grateful for Lionel’s continued service,” said Kevin T. Conroy, the
company’s chairman and chief executive. “Jim’s proven leadership,
managerial capabilities and deep knowledge of governmental and legal
affairs add outstanding depth to the board.
“Maneesh has been a partner in the rebirth of Exact Sciences from the
start. His financial and executive experience, coupled with his
knowledge of the company and the molecular diagnostics industry are a
valuable addition to the board as we move closer to FDA approval and the
launch of Cologuard.
“Lionel’s financial, operational and commercial experience has been
invaluable to us since he joined the board in 2010. We look forward to
Lionel’s continued wise counsel as we launch and commercialize
Cologuard,” Mr. Conroy said.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on
colorectal cancer. The company has exclusive intellectual property
protecting its non-invasive, molecular screening technology for the
detection of colorectal cancer. Stool-based DNA technology is included
in the colorectal cancer screening guidelines of the American Cancer
Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For
more information, please visit the company’s website at www.exactsciences.com.
Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities and Exchange Act of
1934, as amended that are intended to be covered by the “safe harbor”
created by those sections. Forward-looking statements, which are based
on certain assumptions and describe our future plans, strategies and
expectations, can generally be identified by the use of forward-looking
terms such as “believe,” “expect,” “may,” “will,” “should,” “could,”
“seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable
terms. Forward-looking statements in this news release may address the
following subjects among others: statements regarding the sufficiency of
our capital resources, expectations concerning our ability to secure and
the timing of FDA approval for our Cologuard test, our ability to secure
favorable reimbursement rates from Medicare and other third-party
payors, timing of our launch of a commercial product, our estimates of
the available market size and our potential penetration, expected
research and development expenses, expected general and administrative
expenses and our expectations concerning our business strategy.
Forward-looking statements involve inherent risks and uncertainties
which could cause actual results to differ materially from those in the
forward-looking statements, as a result of various factors including
those risks and uncertainties described in the Risk Factors and in
Management’s Discussion and Analysis of Financial Condition and Results
of Operations sections of our most recently filed Annual Report on Form
10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge
you to consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only as
of the date made. Except as otherwise required by the federal securities
laws, we disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained herein
(or elsewhere) to reflect any change in our expectations with regard
thereto or any change in events, conditions or circumstances on which
any such statement is based.
Exact Sciences Corp.
Senior Manager, Marketing
The Luminis Group Ltd
Exact Sciences Corp.
Source: Exact Sciences Corp.